Senolytic drugs restore stem cell function in aged mice, raising hopes for treating sarcopenia and frailty in humans. But safety hurdles remain.
Cellular senescence is stealing stem cells’ regenerative power. But new research suggests senolytic drugs could reverse this decline.
As we age, our tissues lose their ability to regenerate. This decline is driven, in part, by the accumulation of senescent cells—aged cells that refuse to die but instead secrete inflammatory factors that harm their neighbors. Now, a wave of recent studies suggests that eliminating these senescent cells with senolytic drugs can restore stem cell function, potentially reversing aspects of aging. But can these findings translate to humans?
The Senescence-Stemness Competition
Stem cells are the body’s repair crew, dividing to replace damaged or worn-out cells. With age, however, stem cells themselves become fewer and less functional. One reason is that senescent cells create a toxic microenvironment. They pump out inflammatory signals—the senescence-associated secretory phenotype (SASP)—that inhibit stem cell proliferation and differentiation. This competition between senescence and stemness lies at the heart of age-related tissue decline.
In muscle, for example, satellite cells (muscle stem cells) are essential for repair after injury. In aged mice, these cells are surrounded by senescent cells. A July 2024 study published in Nature Aging demonstrated that clearing senescent cells with the senolytic combination dasatinib and quercetin rejuvenates aged muscle stem cells, restoring their regenerative capacity. Mice treated with these drugs showed improved muscle regeneration after injury, comparable to young mice.
Similarly, in bone marrow, hematopoietic stem cells (HSCs) produce all blood cells. A June 2024 report from the Buck Institute linked senescence in bone marrow niche cells to impaired hematopoiesis. The researchers found that the senolytic navitoclax, which inhibits anti-apoptotic proteins BCL-2/BCL-xL, effectively eliminated senescent cells and restored HSC function. This study, led by Dr. Judith Campisi, a pioneer in senescence research, suggests that navitoclax could be repurposed to treat age-related anemia or immune decline.
From Mice to Humans: Recent Breakthroughs
The mouse studies are compelling, but human translation is the next frontier. Several clinical trials are already testing senolytics for age-related conditions. Unity Biotechnology’s UBX0101, a senolytic targeting p53, was tested in a Phase 2 trial for osteoarthritis of the knee. Although the trial did not meet its primary endpoint, it showed reduced pain in a subgroup, hinting at potential. Meanwhile, dasatinib and quercetin have been used in pilot studies for idiopathic pulmonary fibrosis and chronic kidney disease, with some success in reducing senescent cell burden.
A 2024 preprint from the Mayo Clinic further supports the approach. The team, led by Dr. James Kirkland, measured senescent cell burden via p16INK4a expression in human fat tissue and found it correlated with reduced hematopoietic stem cell clonogenicity. This provides a biomarker to monitor senolytic efficacy in clinical trials. Kirkland’s group is now planning a trial of dasatinib and quercetin in older adults with frailty.
Navitoclax, already FDA-approved for chronic lymphocytic leukemia (CLL), is being repurposed. Its advantage is that it targets BCL-2 family proteins, which are overexpressed in senescent cells. However, it also kills platelets, causing thrombocytopenia, which may limit its use in healthy older adults. Researchers are developing next-generation navitoclax derivatives with fewer side effects.
Repurposing Cancer Drugs for Aging
Navitoclax’s journey from oncology to aging is illustrative of a broader trend. Many senolytics were originally developed as cancer therapies, where they induce apoptosis in tumor cells. The same mechanisms can selectively eliminate senescent cells, which also rely on anti-apoptotic pathways for survival. This repurposing reduces development time and cost, as safety data already exist.
But concerns remain. Senescent cells are not always harmful; they play roles in wound healing and tumor suppression. Indiscriminately killing them could increase cancer risk. Furthermore, senolytic drugs may inadvertently damage other cell types. For instance, dasatinib is a tyrosine kinase inhibitor that can cause fluid retention and fatigue. These side effects may be acceptable in terminal cancer patients but not in relatively healthy older adults seeking rejuvenation.
To address this, researchers are exploring intermittent dosing. The Mayo Clinic protocol for dasatinib and quercetin involves only a few days of treatment, followed by weeks off, to minimize toxicity while periodically clearing senescent cells. Early data suggest this approach is safe and reduces senescent cell markers.
The Translational Hurdle
Despite the promise, translating mouse results to humans is fraught with challenges. Aging in humans is multifactorial, and senescent cells are just one piece. Moreover, mouse studies often use accelerated aging models or very old mice, which may not reflect human physiology. The Senolytic Trials in Humans are just beginning, and results are mixed.
Another challenge is targeting the right tissues. Senescent cells accumulate in different organs at different rates. A systemic senolytic might clear cells in the liver but miss those in the brain. Local delivery, such as intra-articular injection for osteoarthritis, may be more effective but limits systemic benefits.
Nevertheless, the evidence is building. The p16INK4a biomarker is now being used in clinical trials to measure senolytic efficacy, allowing personalized dosing. If early trials show safety and efficacy, larger trials targeting frailty, sarcopenia, and immunosenescence could begin within a few years.
Future Directions
The next five years will be critical. Researchers are developing better senolytics with fewer side effects. Combinations of drugs, like dasatinib and quercetin, may be optimized. Additionally, senomorphic drugs—which suppress the SASP without killing senescent cells—offer another avenue. Metformin, for example, has senomorphic properties and is already widely used for diabetes.
As the field advances, the dream of rejuvenating aged stem cells may become a clinical reality. For now, the studies on dasatinib, quercetin, and navitoclax provide a proof of concept that targeting senescence can restore stem cell function. Whether this translates to healthier aging in humans remains to be seen, but the path is clearer than ever.
In the broader context, the interest in senolytics is part of a larger shift in aging research. Previous rejuvenation strategies, such as parabiosis (connecting young and old mice) and mTOR inhibitors (like rapamycin), have shown similar promise but also side effects. Parabiosis is not feasible in humans, and rapamycin can impair immune function. Senolytics offer a more targeted approach, but their long-term safety is unknown.
Historically, the idea that removing ‘zombie cells’ could rejuvenate tissues dates back to 2011, when the first senolytic compounds were identified. Since then, the field has exploded, with dozens of companies racing to develop therapeutics. The recent studies from Nature Aging and the Buck Institute are milestones, but they build on decades of fundamental research on cellular senescence.
Clinically, if senolytics prove safe, they could be used not just for sarcopenia and frailty but for a range of age-related diseases, from atherosclerosis to neurodegeneration. Already, trials are underway for Alzheimer’s disease using dasatinib and quercetin. The potential is enormous, but caution is warranted. The history of anti-aging medicine is littered with false starts. Senolytics, however, are grounded in robust biology and are being tested rigorously. The next few years will tell if they live up to the hype.
